clinical trial · NCT06195072
Platform Clinical Study for Conquering Scleroderma
Scleroderma Research Foundation, Inc.·phase2·recruiting·n = 400
Interstitial Lung Disease Due to Systemic DiseaseSclerodermaAmlitelimabBI 1015550 (Nerandomilast)Placebo
brief summary
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
started
Apr 15, 2024
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Feb 4, 2026
official title
Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol